Company

Quince Therapeutics SpA

Biotechnology Research Bresso, Milano, IT 19 employees GNTA

Employees: 19
Contacts: 2
Emails: 2

erydel.com LinkedIn

Quince Therapeutics SpA Overview

Headquarters: Bresso, Milano, IT
Website: erydel.com
Industry: Biotechnology Research
Employees: 19
Founded: 2007
Stock Symbol: GNTA
NAICS: Research and Development in Biotechnology (except Nanobiotechnology)

Keywords

red blood cell biotech platform rare disease ataxia telangiectasia enzyme replacement science and technology orphan drugs

About Quince Therapeutics SpA

EryDel is a multi-asset, clinical stage biopharmaceutical company headquartered in Bresso (Milan), Italy dedicated to developing and commercializing novel treatments for rare diseases with high unmet need. In 2018 EryDel received the “Most Innovative StartUp Italia Award” chosen from startups across all industries. EryDel specializes in the delivery of drugs using the patient’s own red blood cells. The lead product candidate, EryDex, is currently in Phase III development for the treatment of Ataxia Telangiectasia (AT), a rare neurological disorder for which no established therapy is currently available. EryDex received Orphan Drug designation for the treatment of AT both from FDA and EMA

Quince Therapeutics SpA Contact Details

People in AeroLeads: 4
With contact data: 2
Email contacts: 2; 50.0% coverage

Quince Therapeutics SpA Org Chart

Sample employees and titles

Name	Title	Location	Contact
Chiara Palmieri		Mirandola, Emilia-romagna, Italy	Email
Fabiola Ottani	Regulatory Affairs Manager, Medical Device	Bagnolo in Piano, Emilia-romagna, Italy	View
Barbara Guerrieri	Cmc , Associate Director	Reggio Emilia, Emilia-romagna, Italy	View
Luca Manganelli	Software, Cybersecurity and Electronic Engineer Manager & Security Manager Presso Quince Therapeutics Spa	Bologna, Emilia-romagna, Italy	Email